Experience in IVIg Therapy for Selected Women with Recurrent Reproductive Failure and NK Cell Expansion. (10th March 2014)

• Record Type: Journal Article
• Authors: Ramos‐Medina, Rocio; García‐Segovia, Aurea; Gil, Juana; Carbone, Javier; Aguarón de la Cruz, Angel; Seyfferth, Ansgar; Alonso, Bárbara; Alonso, Jorge; León, Juan A.; Alecsandru, Diana; Meliá, Elena; Carrillo de Albornoz, Elena; Ordoñez, Daniel; Santillán, Isabel; Verdú, Victoria; Garcia Ruiz de Morales, Jose Maria; López‐Hoyos, Marcos; López Larios, Arturo; Sampalo, Almudena; Caballero, Pedro; Ortiz Quintana, Luis; Fernández‐Cruz, Eduardo; Sánchez‐Ramón, Silvia
• Is Part Of: American journal of reproductive immunology. Volume 71:Number 5(2014:May)
• Page Start: 458
• Page End: 466
• Publication Date: 2014-03-10
• Subjects: Human reproduction -- Immunological aspects -- Periodicals; 616.69206
• DOI: 10.1111/aji.12217
• Languages: English
• ISSNs: 1046-7408

Abstract

<abstract abstract-type="main" id="aji12217-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="aji12217-sec-0001" sec-type="section"> <title>Problem</title> <p>Recurrent reproductive failure (RRF) has been associated with expansion of circulating NK cells, key cells for maternal tolerance, decidual vasculogenesis and embryo growth. This study reports our experience in intravenous immunoglobulin (IVIg) therapy of a large cohort of women with RRF with expanded circulating NK and/or NKT‐like cells (blood NKT cells are a heterogeneous subset of T cells that share properties of both T cells and NK cells).</p> </sec> <sec id="aji12217-sec-0002" sec-type="section"> <title>Method of study</title> <p>Observational study of RRF women with NK or NKT‐like expansion (>12% or 10% cutoff levels of total lymphocytes, respectively), treated with IVIg for the next gestation.</p> </sec> <sec id="aji12217-sec-0003" sec-type="section"> <title>Results</title> <p>By multivariant logistic regression analysis after adjusting for age, NK cells subsets and other therapies, IVIg significantly improved the live birth rate to 96.3% in women with recurrent miscarriage (RM) compared with 30.6% in case not receiving IVIg (<italic>P</italic> < 0.0001). In women with recurrent implantation failure (RIF), in comparison with women not receiving IVIg, treatment increased the pregnancy rate from 26.2 to 93.8% (<italic>P</italic> ≤ 0.0001) and the live birth rate from 17.9 to 80.0% in RIF (<italic>P</italic> ≤ 0.0001).</p> </sec> <sec id="aji12217-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Immunomodulation with IVIg in our selected group of RRF patients with immunologic alterations enhanced clinical pregnancy and live birth rates. Our results may facilitate the design of future clinical trials of IVIg in this pathology.</p> </sec> </abstract>